Biomarkers for the Prediction and Early Diagnosis of Diabetes and Diabetes-related Cardiovascular Complications (PREDICCt)
– University Medical Center Groningen (UMCG), Groningen
Principal Investigator: Prof. Dr. M. H. Hofker
CTMM Program manager: Erna Erdtsieck-Ernste
Type 2 Diabetes Mellitus (DM2) effects more than 500,000 people in the Netherlands alone, and by the time it is diagnosed, life-threatening complications such as myocardial infarction, cerebro-vascular incidents and kidney failure have often occurred. Early diagnosis and treatment of DM2 is therefore essential to reduce the burden of this disease and its complications on individuals and the healthcare system.
The PREDICCt (Prevention and Early Detection of Cardiovascular Complications in DM2) consortium will combine the latest insights into the causes of DM2 with innovative technologies to identify risk-indicators (biomarkers) for DM2 and DM2-related complications with the objective of:
- identifying people at risk of obesity and DM2
- identifying DM2 patients with an increased risk of cardiovascular complications
- gaining insight into strategies to diagnose diabetic vascular disease at an early stage
In the search for these biomarkers, the PREDICCt project will adopt two complementary strategies. Firstly, by leveraging important new insights into the phenomena leading to DM2 and its complications in order to develop novel technologies for visualizing the associated processes, and identifying biomarkers that represent a relation between these phenomena and DM2. Secondly by identifying biomarkers in DM2 patients in whom the presence or absence of complications has been established, it will provide accurate information on their disease phase.
Prof. Dr. M. H. Hofker is head of the laboratory of Molecular Genetics at the UMCG (University Medical Center Groningen). He studied Biology at the University of Leiden where he obtained a PhD on the development of genetic markers for the detection of inherited diseases. He holds a chair in Molecular Genetics, in particular on metabolic and cardiovascular diseases in relation to inflammation and genetic predisposition. Currently, he is coordinator of the IOP-genomics-program that focuses on the role of inflammation in obesity induced diabetes.
Prof. Dr. M. H. Hofker:
"The positive decision of the CTMM board to fund PREDICCt has met enormous excitement among the diabetes researchers. For us, it is an excellent opportunity to collaborate at a large scale within the Netherlands. During the preparation of the proposal, the enthusiasm increased as the application deadline came nearer and it is rewarding that we can bring the intended consortium into reality very soon."
- BG Medicine
- Da Vinci Europe Laboratory Solutions BV
- Danone Research
- Hans Mak Instituut
- Hycult Biotech
- MSD Oss
- Topic Embedded Systems
- U-Protein Express
- Technische Universiteit Eindhoven (TU/e)
- Universitair Medisch Centrum Utrecht (UMCU)
- Maastricht University Medical Center+ (Maastricht UMC+)
- Leids Universitair Centrum (LUMC)
- Universitair Medisch Centrum Groningen (UMCG)
- Universitair Medisch Centrum St.-Radboud
- Leiden University
- TNO Quality of life
The CTMM Predicct project also receives additional contribution from three supporting foundations:
More information on the partners and supporting foundations (in Dutch
): click here
Status of the Predicct project end of 2009: PDF
Predicct project presentation at the CTMM Annual Meeting 2010: PDF
In response to the first call for project proposals in 2007, the Center for Translational Molecular Medicine (CTMM) announced on April 1, 2008, that nine first-call projects would receive research funding amounting to a total of 150 million Euro. On March 10, 2009, it announced that eight new project proposals, submitted in the fall of 2008 in response to the second call for proposals, will receive funding amounting to a total of almost another 100 million Euro.
All Dutch university medical centers, plus several universities, a broad spectrum of small and medium-sized enterprises, major industry leaders including Philips and DSM, and the Dutch Government are involved.
The funding is provided by the Dutch government, industry and academia. The research is focused firmly on the ‘translational’ aspects of molecular medicine so that results can be applied as quickly as possible to actual patient care.
Predicct is one of the projects from the first call.